Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine.
Child–Pugh classification
fenfluramine
hepatic impairment
norfenfluramine
pharmacokinetics
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
received:
05
01
2024
accepted:
23
02
2024
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
aheadofprint
Résumé
Fenfluramine (Fintepla
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : UCB Biosciences
Informations de copyright
© 2024 UCB Biopharma SRL. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d‐fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30(3):715‐721.
Fuxe K, Farnebo LO, Hamberger B, Ogren SO. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5‐hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgrad Med J. 1975;51(suppl 1):35‐45.
Baumann MH, Bulling S, Benaderet TS, et al. Evidence for a role of transporter‐mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates. Neuropsychopharmacology. 2014;39(6):1355‐1365.
Porter RH, Benwell KR, Lamb H, et al. Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells. Br J Pharmacol. 1999;128(1):13‐20.
Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5‐HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836‐2841.
Sourbron J, Smolders I, de Witte P, Lagae L. Pharmacological analysis of the anti‐epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.
Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for sigma‐1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22(16):8416.
Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double‐blind, placebo‐controlled trial. Lancet. 2019;394(10216):2243‐2254.
Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment‐resistant seizures in patients with Dravet syndrome receiving stiripentol‐inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300‐308.
Sullivan J, Lagae L, Cross JH, et al. Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo‐controlled clinical trial. Epilepsia. 2023;64(10):2653‐2666.
Knupp K, Scheffer I, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox‐Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554‐564.
Devinsky O, King L, Schwartz D, Conway E, Price D. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021;62(7):e98‐e102.
Martin P, Czerwiński M, Limaye PB, et al. In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. Pharmacol Res Perspect. 2022;10(3):e00958.
Bruce RB, Maynard WR Jr. Fenfluramine metabolism. J Pharm Sci. 1968;57(7):1173‐1176.
Marchant NC, Breen MA, Wallace D, et al. Comparative biodisposition and metabolism of 14C‐(+/‐)‐fenfluramine in mouse, rat, dog and man. Xenobiotica. 1992;22(11):1251‐1266.
Gammaitoni A, Smith S, Boyd B. The lack of effect of food on the pharmacokinetics of ZX008 (fenfluramine oral solution): results of a single‐dose, two‐period crossover study. Clin Ther. 2018;40(8):1338‐1346.
Boyd B, Smith S, Gammaitoni A, Galer BS, Farfel GM. A phase I, randomized, open‐label, single‐dose, 3‐period crossover study to evaluate the drug‐drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(1):11‐19.
Zogenix Inc. Data on file. Zogenix (now a part of UCB); 2022.
Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490‐504.
Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608‐611.
Tsoris A, Marlar CA. Use of the child Pugh score in liver disease. In: StatPearls. StatPearls Publishing LLC; 2023.
US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. Accessed November 12, 2018. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf
Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care. 2012;16(2):211.
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis ‐ a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132‐1156.
Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450–mediated metabolism. Clin Pharmacol Ther. 2006;80(3):235‐245.
El‐Khateeb E, Achour B, Al‐Majdoub ZM, Barber J, Rostami‐Hodjegan A. Non‐uniformity of changes in drug‐metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm. 2021;18(9):3563‐3577.
Greenblatt DJ, Sellers EM, Koch‐Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol. 1982;22(5‐6):259‐263.
Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156‐164.
Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23‐36.
Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug‐induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS). Epilepsy Behav. 2021;117:107832.
Watkins PB, Church RJ, Li J, Knappertz V. Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase I clinical trial. Clin Pharmacol Ther. 2021;109(5):1224‐1231.
Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug‐resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011‐2020.
Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox‐Gastaut syndrome. N Engl J Med. 2018;378(20):1888‐1897.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox‐Gastaut syndrome (GWPCARE4): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2018;391(10125):1085‐1096.
Fintepla 2.2 mg/ml oral solution. Patient information leaflet. UCB Pharma SA; 2023.
Fintepla (fenfluramine) oral solution. Package insert. UCB, Inc.; 2023.
Fintepla oral solution 2.2 mg/mL. Package insert. UCB Japan Co. Ltd.; 2023.